Justinian Liu

Despite the twists and turns, 2022 turned out to be a banner year for National Reimbursement Drug List’s new inclusions—and with welcomed upgrades to bidding and renewal rules.

Its use enables key processes such as early access, regulatory approval, and reimbursement listing.